Detalles de la búsqueda
1.
Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.
Ther Drug Monit
; 44(2): 290-300, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34387220
2.
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
Scand J Gastroenterol
; 55(8): 884-890, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32631131
3.
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease.
Nat Commun
; 15(1): 4567, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38830848
4.
The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980-2017).
J Crohns Colitis
; 17(2): 259-268, 2023 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36125076
5.
Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study.
BMJ Open
; 12(6): e055779, 2022 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35760545
6.
Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.
NEJM Evid
; 1(8): EVIDoa2200061, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-38319804
7.
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
United European Gastroenterol J
; 9(1): 91-101, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33079627
Resultados
1 -
7
de 7
1
Próxima >
>>